Madrigal Pharma more than doubles after liver drug study success
By Tamara Mathias (Reuters) – Madrigal Pharmaceuticals Inc’s shares more than doubled after mid-stage trial data showed its lead drug reduced liver fat in patients with fatty liver disease, placing it ahead of larger...
Read More